Pro-inflammatory cytokine network in intestinal tissue

The pro-inflammatory cytokine network in intestinal tissue is a complex signaling system involving proteins such as Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-6 (IL-6), and the Interleukin-12/23 axis, which are central to the pathogenesis of inflammatory bowel disease (IBD) (Neurath, 2014). In a healthy gut, these cytokines facilitate immune surveillance and epithelial repair, but their dysregulation leads to chronic inflammation and tissue destruction seen in Crohn's disease and ulcerative colitis (Friedrich et al., 2019). Therapeutic strategies target this network by using monoclonal antibodies to neutralize specific cytokines, such as Infliximab for TNF-alpha or Ustekinumab for the p40 subunit of IL-12 and IL-23. Additionally, small molecule inhibitors of Janus kinases (JAKs) are used to block the downstream signaling pathways shared by multiple cytokines in this network (Mao et al., 2017). While effective, modulating this network carries risks of systemic immunosuppression and increased susceptibility to opportunistic infections (Salas et al., 2020). Monitoring the activity of this network is typically achieved through biomarkers like fecal calprotectin and C-reactive protein, which reflect the degree of mucosal inflammation.

Other names

Intestinal inflammatory cytokine milieuIBD cytokine pathwayGut inflammatory signaling networkIntestinal cytokine cascade

The network is modulated through the neutralization of specific pro-inflammatory cytokines (e.g., TNF-alpha, IL-12, IL-23) or the inhibition of downstream intracellular signaling pathways, such as the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway, to resolve chronic intestinal inflammation.